TARLOX-TKI FOR DUMMIES

Nilotinib is currently approved by FDA as entrance-line therapy for Long-term stage CML and for patients that are resistant or intolerant to imatinib.The stunning final results shown with imatinib mesylate (aka Gleevec) targeting split point cluster (Bcr)-Abelson (Abl) fusion protein in Long-term myeloid leukemia (CML) result in the development of